

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2023/196086 A2

(43) International Publication Date
12 October 2023 (12.10.2023)

(51) International Patent Classification:

A61K 31/5377 (2006.01) A61K 41/00 (2020.01)

(21) International Application Number:

PCT/US2023/015097

(22) International Filing Date:

13 March 2023 (13.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/329,090 08 April 2022 (08.04.2022) US

(71) Applicant: **MIRATI THERAPEUTICS, INC.** [US/US];
3545 Cray Court, San Diego, CA 92121 (US).

(72) Inventors: **HALING, Jacob**; c/o Mirati Therapeutics, Inc.,
3545 Cray Court, San Diego, CA 92121 (US). **KHARE,**
Shilpi; c/o Mirati Therapeutics, Inc., 3545 Cray Court, San
Diego, CA 92121 (US).

(74) Agent: **POLYAKOV, Mark, V.** et al.; Wood, Phillips,
Katz, Clark & Mortimer, 500 West Madison Street, Suite
1130, Chicago, IL 60661 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,
NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(54) Title: COMBINATION THERAPIES COMPRISING A SOS1 INHIBITOR AND AN EGFR INHIBITOR

(57) Abstract: The present invention relates to combination therapies for treating cancers associated with genetic alterations of the MAPK pathway and/or EGFR. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SOS1 inhibitor and an EGFR inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use therefor.

WO 2023/196086 A2